血清 CA125、HE4 和 TK1 联合检测在卵巢癌诊断中的应用价值研究。

Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer.

机构信息

Department of Obstetrics and Gynecology, Changshu No. 1 People's Hospital, Changshu, Jiangsu Province, China.

出版信息

Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4536-4541.

Abstract

OBJECTIVE

To explore the diagnostic value of joint examination of cancer antigen 125 (CA125), thymidine kinase-1 (TK1) and human epididymis protein 4 (HE4) in the serum of patients with ovarian cancer.

PATIENTS AND METHODS

A total of 75 ovarian cancer specimens (ovarian cancer group), 40 benign ovarian specimens (benign group) and 35 ovarian specimens of healthy women (normal control group) were collected. The serum levels of HE4, CA125 and TK1 and the positive detection rates in the three groups were compared. Meanwhile, the sensitivity and specificity of the three tumor markers in the diagnosis of ovarian cancer in the three groups were compared.

RESULTS

The levels of HE4, CA125 and TK1 in the ovarian cancer group were significantly higher than those in the control group (p<0.05), and those in the ovarian cancer group were significantly higher than those in the benign group (p<0.05). The positive rates of CA125 as well as TK1 in the ovarian cancer group and the benign group were significantly higher than those in the control group (p<0.05), and those in the ovarian cancer group were significantly higher than those in the benign group (p<0.05). In the detection of an individual tumor marker, the sensitivity of CA125 was the highest, followed by HE4. The specificity of HE4 was the highest, followed by TK1. For the combination of two tumor markers, the sensitivity of CA125+HE4 ranked the first (92.18%), and the specificity of TK1+HE4 ranked the first (88.37%). The sensitivity and specificity of the joint detection of CA125+HE4+TK1 were 94.18% and 79.53%, respectively. The sensitivity of the joint detection of CA125+HE4+TK1 was significantly higher than that of the detection of a single tumor marker and that of joint detection of two tumor markers (p<0.05).

CONCLUSIONS

Combined detection of CA125, HE4 and TK1 can significantly improve the sensitivity in the diagnosis of ovarian cancer.

摘要

目的

探讨联合检测癌抗原 125（CA125）、胸苷激酶-1（TK1）和人附睾蛋白 4（HE4）在卵巢癌患者血清中的诊断价值。

方法

收集卵巢癌标本 75 例（卵巢癌组）、良性卵巢标本 40 例（良性组）和健康女性卵巢标本 35 例（正常对照组）。比较三组血清 HE4、CA125、TK1 水平及阳性检出率，同时比较三组肿瘤标志物单独及联合检测对卵巢癌的诊断灵敏度和特异度。

结果

卵巢癌组 HE4、CA125、TK1 水平明显高于对照组（p<0.05），卵巢癌组明显高于良性组（p<0.05）。卵巢癌组和良性组 CA125、TK1 阳性率明显高于对照组（p<0.05），卵巢癌组明显高于良性组（p<0.05）。单项肿瘤标志物检测中，CA125 灵敏度最高，HE4 特异度最高。两种肿瘤标志物联合检测中，CA125+HE4 灵敏度最高（92.18%），TK1+HE4 特异度最高（88.37%）。CA125+HE4+TK1 联合检测的灵敏度和特异度分别为 94.18%和 79.53%。CA125+HE4+TK1 联合检测的灵敏度明显高于单项肿瘤标志物和两种肿瘤标志物联合检测（p<0.05）。